Rewiring innate and adaptive immunity with TLR9 agonist to treat osteosarcoma.

ABSTRACT:

Background

Osteosarcoma (OS) is the most common primary bone tumor in children and adolescent. Surgery and multidrug chemotherapy are the standard of treatment achieving 60-70% of event-free survival for localized disease at diagnosis. However, for metastatic disease, the prognosis is dismal. Exploiting immune system activation in the setting of such unfavorable mesenchymal tumors represents a new therapeutic challenge.

Methods

In immune competent OS mouse models bearing two contralateral lesions, we tested the efficacy of intralesional administration of a TLR9 agonist against the treated and not treated contralateral lesion evaluating abscopal effect. Multiparametric flow cytometry was used to evaluate changes of the tumor immune microenviroment. Experiments in immune-defic

SUBMITTER: Cascini C 

PROVIDER: S-EPMC10291774 | biostudies-literature | 2023 Jun

REPOSITORIES: biostudies-literature